Skip to content
10-K

Annual Report

Inhibitor Therapeutics, Inc. INTI

0001641172-25-001190

← back to feed
Filed
Mar 28, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 28, 2025 172.32M sh
Shares Diluted FY 2024 · Dec 31, 2023 171.95M sh
Operating Cash Flow FY 2024 · Dec 31, 2023 −$2.7M
Cash And Equivalents FY 2024 · Dec 31, 2023 $8.84M
Current Liabilities FY 2024 · Dec 31, 2023 $665.16K
Total Liabilities FY 2024 · Dec 31, 2023 $3.67M
Current Assets FY 2024 · Dec 31, 2023 $8.95M
Total Assets FY 2024 · Dec 31, 2023 $8.95M
Eps Diluted FY 2024 · Dec 31, 2023 −$0.02
Eps Basic FY 2024 · Dec 31, 2023 −$0.02
Sga Expense FY 2024 · Dec 31, 2023 $2.02M
Rd Expense FY 2024 · Dec 31, 2023 $1.38M
Net Income FY 2024 · Dec 31, 2023 −$3.03M
Operating Income FY 2024 · Dec 31, 2023 −$3.4M
Stockholders Equity FY 2024 · Dec 31, 2022 $8.3M